A recent decision from the United States District Court for the District of Columbia continues to give significant deference to the U.S. Department of Health and Human Services’ (HHS) interpretation of the Anti-Kickback and...more
5/2/2025
/ Advisory Opinions ,
Anti-Kickback Statute ,
Appeals ,
Beneficiary Inducement ,
Biotechnology ,
Department of Health and Human Services (HHS) ,
Enforcement Actions ,
Healthcare Fraud ,
Judicial Authority ,
Litigation Strategies ,
OIG ,
Pharmaceutical Industry ,
Statutory Interpretation
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling that the Anti-Kickback Statute (“AKS”) requires the government to prove that an AKS violation was the...more
Courts continue to reject aggressive Anti-Kickback Statute (“AKS”) allegations. Most recently, on January 6, 2025, Judge Patti Saris of the U.S. District Court for the District of Massachusetts dismissed a qui tam action...more
1/8/2025
/ Anti-Kickback Statute ,
Causation ,
Enforcement Actions ,
False Claims Act (FCA) ,
Healthcare ,
Healthcare Fraud ,
Medicare ,
Statutory Interpretation ,
Summary Judgment ,
Whistleblowers ,
White Collar Crimes